Jurkat-NFAT-Luc2-CAR19-Stable Cell Line
| Catalog Number | CBCL-0278 |
| Price | Online Inquiry |
| Unit Quantity | 1 x 10^6 cells / 1.0 ml |
Introduction
This stable Jurkat cell line expresses exogenous human CAR19 and luciferase under the control of the NFAT signaling pathway, enabling studies of CAR19-mediated signaling and NFAT-dependent gene expression.
Application
Drug screening and biological assays
Background
CAR19 is a chimeric antigen receptor that targets CD19, a B cell surface marker. It is used in CAR-T cell therapy for treating B cell malignancies.
Product Information
| Category | Luciferase Reporter Cell Lines |
| Cell Line Name | Jurkat-NFAT-Luc2-CAR19-Stable Cell Line |
| Protein Family | Chimeric antigen receptors family |
| Gene | CAR19 |
| Species | Human |
| Host Cell Line | Jurkat |
| Cell Type | Human T-cell leukemia |
| Morphology | Lymphoblastoid |
| Growth Properties | Suspension |
| Storage Method | Frozen in liquid nitrogen. |
| Stability | Validated for at least 10 passages |
| Mycoplasma | Negative |
| Sterility Testing | Negative |
| Shipping | Shipping in dry ice |
| Caution | For Research Use Only |
For research use only. Not for any other purpose.